Experimental drug ampligen takes on chronic fatigue

NCT ID NCT00215813

TEMPORARILY_NOT_AVAILABLE Disease control Sponsor: AIM ImmunoTech Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests an experimental drug called Ampligen (rintatolimod) in people with severe chronic fatigue syndrome (CFS). Participants receive twice-weekly IV infusions over several months. The goal is to see if the drug can ease symptoms and improve quality of life for those who have been sick for at least a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ampligen (rintatolimod)
What this could lead to: If it works, this could point toward a treatment option for severe chronic fatigue syndrome, potentially reducing symptoms and improving daily function.
What could go wrong: This is an early open-label study with no placebo group, so results may be biased. The drug is not yet approved for CFS, and side effects or lack of benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC FATIGUE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myalgic encephalomeyelitis/chronic fatigue syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC FATIGUE SYNDROME

Contacts and locations

Locations

Hunter-Hopkins Center, PA

Charlotte, North Carolina, 28210, United States
Sierra Internal Medicine

Incline Village, Nevada, 89451, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.